The RAS targeting therapies market is anticipated to grow at an annualized rate of over 50%

More than 155 drug candidates targeting the RAS gene are currently being investigated
Over 70% of the therapies are being evaluated across preclinical and clinical stages, either as monotherapies or in combination with other products. Majority of the RAS targeting therapies (79%) are designed for administration via the oral route.

22,000+ patients have been enrolled in over 120 clinical trials, worldwide
Clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 5%, in the past three years. Of the total number of trials, close to 25% of the studies have already been completed, while 60% are active and still recruiting patients.

Close to 300 articles focused on RAS mutated colorectal cancer have been published
Several industry, as well as non-industry, players engaged in this domain are undertaking numerous initiatives to identify and develop novel RAS targeting therapies. Majority of the authors affiliated to deemed universities have published articles focused on KRAS (80%), in last one year.

Leave a Reply

Your email address will not be published. Required fields are marked *

The RAS targeting therapies market is anticipated to grow at an annualized rate of over 50%

The research includes detailed profiles of 85+ drugs being developed by key players (listed below); each profile further features an overview of the developer, details related to its financials (if available), recent developments, and an informed future outlook.

Amgen
AstraZeneca
BridgeBio
Boehringer Ingelheim
Jacobio Pharmaceuticals
Mirati Therapeutics
Moderna
Novartis
Onconova Therapeutics
Revolution Medicine
Targovax
Verastem Oncology
For additional details, please visit
https://www.rootsanalysis.com/reports/ras-targeting-therapies-market.html

Leave a Reply

Your email address will not be published. Required fields are marked *